Skip to content

Defining the Histopathological Extent of Resection of Brain Metastasis: HighResection Met (HiRes Met) – A Pilot Study

Defining the Histopathological Extent of Resection of Brain Metastasis: HighResection Met (HiRes Met) – A Pilot Study - HiResMet

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037780
Enrollment
30
Registered
2025-09-11
Start date
2023-08-14
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C79.3

Interventions

Group 1: Non-eloquent metastases (supramaximal resection + intraoperative histopathological assessment of resection margins)

Sponsors

Klinik für Neurochirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: non-eloquent tumor location

Exclusion criteria

Exclusion criteria: eloquent tumor location

Design outcomes

Primary

MeasureTime frame
Karnofsky Performance Scale (30 days postoperative)

Secondary

MeasureTime frame
- Number of samples collected: Estimated at a maximum of 25 samples per patient. During resection, up to 5 samples are taken in each direction (ventral, dorsal, caudal, medial, and lateral). - Residual tumor volume, defined as the contrast-enhancing lesion on postoperative MRI, compared retrospectively with conventional resections. - Number of re-resections, performed as a second surgery, compared with the number of re-resections after conventional resection. - Number of premature surgery terminations: Termination criteria are defined as an operative time exceeding more than 25% of the usual duration (or >180 minutes after dural opening). Surgery will also be terminated if eloquent areas are reached, as determined by the intraoperative navigation system, intraoperative neuromonitoring, or the surgeon’s anatomical expertise. - Duration of surgery - Intraoperative complications (hemorrhage, infarction, epileptic seizures, edema, cerebrospinal fluid circulation impairment). - Serious, unexpected, neurological adverse events: -- New postoperative neurological deficit not present preoperatively, persisting for more than 7 days, as transient deficits can occur after standard procedures (e.g., edema-related, SMA lesion after frontal tumor resection causing transient deficits due to involvement of the supplementary motor area). -- Worsening of a preexisting neurological motor deficit by >2 strength grades on the Janda scale. -- Change in vigilance status of >4 points on the Glasgow Coma Scale (GCS), persisting for more than 72 hours. -- New postoperative deficit in standardized neurological testing of language (aphasia, word-finding difficulties) or vision (quadrantanopia, hemianopia), persisting for more than 7 days.

Countries

Germany

Contacts

Public ContactLina-Elisabeth Qasem

Klinik für Neurochirurgie

qasem@med.uni-frankfurt.de+49 69 6301 5295

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026